Taken together, our data clearly indicated that celastrol treatment downregulated Claspin and Bcl-2, at least in part, in an m6A-YTHDF3-mediated manner in pancreatic cancer cells. This evidence concerns the gene CLSPN and familial pancreatic carcinoma.